Compare MDXH & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDXH | MCRB |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.0M | 139.7M |
| IPO Year | 2021 | 2015 |
| Metric | MDXH | MCRB |
|---|---|---|
| Price | $2.30 | $8.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.67 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 156.6K | 42.7K |
| Earning Date | 05-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.31 | N/A |
| P/E Ratio | ★ N/A | $13.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.36 | $0.36 |
| 52 Week High | $5.33 | $29.98 |
| Indicator | MDXH | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 18.64 | 44.12 |
| Support Level | $1.90 | $7.74 |
| Resistance Level | $2.30 | $9.53 |
| Average True Range (ATR) | 0.20 | 0.68 |
| MACD | -0.10 | 0.17 |
| Stochastic Oscillator | 3.45 | 52.74 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.